Innovotech Retains Bloom Burton & Co.
June 16 2011 - 8:00AM
Marketwired
Innovotech Inc. (TSX VENTURE: IOT), a pioneer in the field of
biofilm product development, today announced that it has retained
Bloom Burton & Co., a leading Canadian healthcare investment
banking firm, as a capital markets advisor to help the company grow
its presence in the North American capital markets and to attract
investors with an understanding of healthcare markets.
"We are pleased to have the opportunity to work with Bloom
Burton whose understanding and expertise in both the healthcare and
financial industries will be a significant asset as we continue the
expansion of our products into the market place and increase
shareholder engagement," said Ken Boutilier, President and CEO of
Innovotech.
"We are proud to associate our firm with both the management
team and market opportunities being developed at Innovotech. In our
opinion, Innovotech is tackling serious and growing problems
related to biofilms that have recently become better understood. We
appreciate that Innovotech is using that core understanding to
develop a diverse set of potential solutions for the market across
a number of industries," stated Jolyon Burton, CEO of Bloom Burton
& Co.
About Bloom Burton & Co.
Bloom Burton & Co. is Canada's largest healthcare investment
research and banking group. Bridging the gap between the life
sciences and the capital markets, Bloom Burton provides strategic
advisory and capital raising services for Canadian private and
public healthcare companies. Bloom Burton's clients consist of both
research and commercialization-stage companies that operate in the
biotechnology, pharmaceutical, medical device, diagnostic and
healthcare services industries. The firm primarily attracts its
capital from global healthcare-specialized investors. For
additional information, please visit www.bloomburton.com.
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product
development, focused on providing innovative and practical
solutions to medical, agricultural and industrial problems caused
by microbial biofilms. Biofilms are responsible for a host of
diseases both in human health and agriculture due to their inherent
resistance to existing antibiotics and disinfectants. Aside from
Innovotech's products there are no antibiotics, disinfectants,
diagnostics or regulatory standards designed specifically for
biofilm-forming organisms.
Innovotech has a broad range of products that address the issue
of biofilms within a number of different industries, including
three commercial products, the MBEC Assay™, bioFILM PA™ and
InnovoSCEPT veterinary kits. The MBEC Assay™ is a high throughput
biofilm growth device that was recently approved as an ASTM
International standard. bioFILM PA™ is the first diagnostic kit to
assist physicians in the selection of the most effective
combination antibiotic treatment of patients with biofilm-based
chronic lung infections, while the InnovoSCEPT veterinary kits are
designed to determine the most effective antibiotic treatment for
infections in both large and small animals.
Innovotech also has two products in advanced stages of
development; Agress® is a unique, environmentally friendly seed
treatment and plant spray designed to protect crops against both
bacterial and fungal infections and Sani-Lux™ is a light-activated,
natural hard surface sanitizer.
Connect with us:
Website: www.innovotech.ca
Blog: www.cf-test.ca
Twitter: www.twitter.com/innovotech
Facebook: www.facebook.com/innovotech
This document may contain forward-looking statements that are
predictive in nature and subject to risks and uncertainties that
cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or
contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of
predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in
operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and
potential costs associated with its defense; the Company's exposure
to lawsuits and other matters beyond the control of management.
Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company
undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable
law.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Innovotech Inc. Ken Boutilier President and CEO (780)
448-0585 ext. 221 (780) 424-0941 (FAX) ken.boutilier@innovotech.ca
Innovotech Inc. Amanda Stadel Communications Officer (780) 448-0585
ext. 224 (780) 424-0941 (FAX) amanda.stadel@innovotech.ca
www.innovotech.ca
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024